Maarten van der Doelen

Alkaline phosphatase dynamics during radium-223 therapy in mCRPC patients

Table 2. Overall survival data for the total cohort and the pre-specified subgroups

Median survival (months)

N (%)

95% CI

P

Total cohort

180 (100)

13.5

11.5-15.5

Subgroup

1 Normal baseline ALP,

39 (21.7)

25.4

13.4-37.3

≥10% decline after first injection

2 Normal baseline ALP,

27 (15.0)

18.2

11.4-24.9

<10% decline after first injection

<0.001

3 Elevated baseline ALP,

73 (40.6)

12.9

10.5-15.3

≥10% decline after first injection

4 Elevated baseline ALP,

33 (18.3)

7.9

5.9-9.9

<10% decline after first injection

- Missing ALP dynamics

8 (4.4)

4.2

2.2-6.2

Subgroup 1-2

66 (36.7)

19.5

11.8-27.1

<0.001

Subgroup 3-4

106 (58.9)

10.8

8.2-13.4

Subgroup 1-3

139 (77.2)

15.7

13.0-18.4

<0.001

Subgroup 4

33 (18.3)

7.9

5.9-9.9

ALP, alkaline phosphatase; CI, confidence interval.

6

165